Interferon gamma-1b
- Generic Name
- Interferon gamma-1b
- Brand Names
- Actimmune
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 98059-61-1
- Unique Ingredient Identifier
- 21K6M2I7AG
- Background
Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography.
...
- Indication
Interferon gamma-1b is used for the treatment of Chronic granulomatous disease and Osteopetrosis.
- Associated Conditions
- Chronic Granulomatous Disease (CGD), Severe, malignant Osteopetrosis
- Associated Therapies
- -
Effect of Interferon Gamma As a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo
- Conditions
- Interventions
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 170
- Registration Number
- NCT06694740
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Sawa Ito, MD
- Target Recruit Count
- 45
- Registration Number
- NCT06529731
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 200
- Registration Number
- NCT04979052
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇩🇪Klinikum Der Johann Wolfgang Von Goethe Universitaet, Frankfurt am main, Germany
🇬🇷Hellenic Institute for the Study of Sepsis (HISS), Athens, Greece
Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT03747484
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease
- Conditions
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 9
- Registration Number
- NCT03548818
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
ACTIMMUNE in Intermediate Osteopetrosis
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2024-10-22
- Target Recruit Count
- 5
- Registration Number
- NCT02666768
- Locations
- 🇺🇸
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
Use of ACTIMMUNE in Patients With ADO2
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 12
- Registration Number
- NCT02584608
- Locations
- 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)
- Conditions
- Interventions
- First Posted Date
- 2015-01-15
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- National Eye Institute (NEI)
- Target Recruit Count
- 4
- Registration Number
- NCT02338973
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Interferon Gamma-1b in Friedreich Ataxia (FRDA)
- First Posted Date
- 2013-10-18
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Children's Hospital of Philadelphia
- Target Recruit Count
- 12
- Registration Number
- NCT01965327
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Topical Interferon Gamma-1b for Central Serous Chorioretinopathy
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- National Eye Institute (NEI)
- Target Recruit Count
- 5
- Registration Number
- NCT01468337
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.